Martin Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK discusses biosimilars and the reluctance of the scientific community to accept them. Dr Dyer mentions that we have unknowingly been using biosimilars for years such as rituximab, and they have been working well as expected. Many regulated steps are taken to ensure that the effect of the biosimilar is equivalent to the originator antibody, and there are no known disadvantages to their use. The biggest advantage for using biosimilars is the major reduction in cost for the NHS. This interview was recorded at the 2017 British Society for Hematology (BSH) Annual Scientific Meeting in Brighton, UK. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates